AustinPx

AustinPx is a client-centric Contract Development and Manufacturing Organisation (CDMO) dedicated to assisting pharmaceutical developers in realising the full potential of their drug candidates. ​

Founded in 2007 and headquartered in Georgetown, Texas, AustinPx specialises in overcoming challenges such as poor bioavailability and accelerated development timelines. The company offers a comprehensive suite of services, including preclinical development, formulation development, analytical services, and Good Manufacturing Practice (GMP) manufacturing of oral dosage forms. Their data-driven and technology-agnostic approach ensures that each formulation strategy is tailored to the unique physicochemical characteristics of the molecule and the client's objectives. ​

A hallmark of AustinPx is their proprietary KinetiSol™ Technology, a next-generation amorphous solid dispersion (ASD) platform designed to enhance the bioavailability of poorly soluble active pharmaceutical ingredients (APIs). This solvent-free, fusion-based process offers a smaller ecological footprint, broader formulation design space, and faster processing times compared to traditional ASD technologies. ​

Key Products and Services:

Preclinical Development: Molecule characterisation, preformulation testing, and formulation technology screening, including dry and wet granulations, amorphous dispersions, cyclodextrin complexations, particle size reduction, and lipid-based formulations. ​
Drug Development and Delivery

Formulation Development: Development of drug product intermediates and finished dosage forms such as solutions, suspensions, tablets, and capsules, with expertise in immediate and modified release formulations and bioavailability enhancement technologies. ​

Analytical Services: Comprehensive chemical analysis, dissolution testing, drug product test methods, and GMP stability studies to support preclinical through commercial stages. ​
Drug Development and Delivery

GMP Manufacturing: Capabilities include KinetiSol™ Technology, blending, milling, granulation, encapsulation, tableting, and packaging, supporting the production of clinical trial materials for Phase I/II studies. ​

KinetiSol™ Technology: An innovative platform for producing amorphous solid dispersions, significantly improving the bioavailability of poorly soluble drugs through a solvent-free, fusion-based process. ​

With over a decade of GMP manufacturing experience and a robust quality assurance system, AustinPx is committed to delivering flexible, responsive, and solutions-driven services. Their collaborative approach and dedication to scientific excellence make them a trusted partner in the pharmaceutical development and manufacturing industry.